{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:27Z","timestamp":1792839747427,"version":"4.5.0"},"reference-count":224,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatitis C virus (HCV) has emerged as a major global health concern and, if left untreated, can lead to significant liver damage, including cirrhosis, decompensated liver disease, and hepatocellular carcinoma (HCC). Approximately 40% of patients with HCV infection experience extrahepatic manifestations, including renal involvement. HCV-related renal disease is of significant importance among patients with chronic kidney disease (CKD), leading to higher morbidity and mortality. The renal damage due to HCV infection primarily results from cryoglobulinemia and glomerulonephritis, with conditions such as membranoproliferative glomerulonephritis (MPGN) and membranous nephropathy (MN) being most prevalent. Despite advancements in treatment, including the use of directly acting antiviral agents (DAAs), renal complications remain a significant burden in untreated patients. HCV-positive patients on hemodialysis (HD) or those who have undergone kidney transplantation face increased mortality rates compared to their HCV-negative counterparts. Managing HCV infection before kidney transplantation is crucial to mitigate the risk of HCV-related renal complications. Conversely, kidney transplantation from HCV-infected donors is well established, as post-transplant treatment for HCV is safe and effective, potentially reducing mortality and morbidity for patients on transplant waiting lists. This review aims to provide a comprehensive analysis of the renal manifestations of HCV, emphasizing the importance of early diagnosis and treatment to improve patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm13185536","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T03:34:20Z","timestamp":1726716860000},"page":"5536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Renal Manifestations of Chronic Hepatitis C: A Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-7240","authenticated-orcid":false,"given":"Aalam","family":"Sohal","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 2500, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7889-2997","authenticated-orcid":false,"given":"Carol","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshita","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Punjab Institute of Medical Sciences, Jalandhar 144006, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimran","family":"Kalsi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-4278","authenticated-orcid":false,"given":"Marina","family":"Roytman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California San Francisco, Fresno, CA 93701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref_1","unstructured":"World Health Organisation (2024, May 15). Hepatitis C. Key Facts. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0168-8278(02)00051-X","article-title":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359\u2013362]","volume":"36","author":"Farci","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/hep.510260702","article-title":"The hepatitis C virus: Overview","volume":"26","author":"Purcell","year":"1997","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15992","DOI":"10.3748\/wjg.v20.i43.15992","article-title":"Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy","volume":"20","author":"Preciado","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Stroffolini, T., and Stroffolini, G. (2024). Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review. Viruses, 16.","DOI":"10.3390\/v16071115"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005792-200001000-00005","article-title":"Extrahepatic Manifestations Associated with Hepatitis C Virus Infection: A Prospective Multicenter Study of 321 Patients","volume":"79","author":"Cacoub","year":"2000","journal-title":"Medicine"},{"key":"ref_9","first-page":"65","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"16","author":"Galossi","year":"2007","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/flgastro-2013-100315","article-title":"Extrahepatic manifestations of hepatitis C virus (HCV)","volume":"4","author":"Samuel","year":"2013","journal-title":"Front. Gastroenterol."},{"key":"ref_11","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2015","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.14218\/JCTH.2018.00049","article-title":"HCV Extrahepatic Manifestations","volume":"7","author":"Kuna","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Songtanin, B., and Nugent, K. (2022). Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection. Biology, 12.","DOI":"10.3390\/biology12010023"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S1590-8658(07)80017-X","article-title":"Hepatitis C and kidney disease","volume":"39","author":"Coccoli","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CNP69149","article-title":"Hepatitis C virus-related kidney disease: An overview","volume":"69","author":"Kamar","year":"2008","journal-title":"Clin. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-117-7-573","article-title":"Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia","volume":"117","author":"Misiani","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2006.09.015","article-title":"Multicenter Study on Hepatitis C Virus\u2013Related Cryoglobulinemic Glomerulonephritis","volume":"49","author":"Roccatello","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2893.1998.00097.x","article-title":"Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia","volume":"5","author":"Donada","year":"1998","journal-title":"J. Viral Hepat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1386-6346(03)00189-X","article-title":"Detection, using a novel method, of a high prevalence of cryoglobulinemia in persistent hepatitis C virus infection","volume":"27","author":"Okuse","year":"2003","journal-title":"Hepatol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ki.1994.393","article-title":"Renal manifestations of hepatitis C virus infection","volume":"46","author":"Johnson","year":"1994","journal-title":"Kidney Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000491629","article-title":"Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA Glomerulonephritis","volume":"8","author":"Hanna","year":"2018","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101017","DOI":"10.1016\/j.disamonth.2020.101017","article-title":"Hepatitis C and Treatment in Patients with Chronic Kidney Disease","volume":"67","author":"Jalota","year":"2021","journal-title":"Disease-a-Month"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2019.04.014","article-title":"Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia","volume":"71","author":"Alavi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13337-017-0393-5","article-title":"Hepatitis C infection in renal transplantation: Pathogenesis, current impact and emerging trends","volume":"28","author":"Kesiraju","year":"2017","journal-title":"VirusDisease"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fabrizi, F., Cerutti, R., and Messa, P. (2021). Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis. Pathogens, 10.","DOI":"10.3390\/pathogens10091149"},{"key":"ref_26","first-page":"687","article-title":"Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation","volume":"14","author":"Latt","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection","volume":"328","author":"Johnson","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A Role for Hepatitis C Virus Infection in Type II Cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","article-title":"Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease","volume":"61","author":"Fabrizi","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/sdi.12759","article-title":"The association of hepatitis C infection with the onset of CKD and progression into ESRD","volume":"32","author":"Henson","year":"2019","journal-title":"Semin. Dial."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s10620-016-4199-x","article-title":"Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)","volume":"61","author":"Moorman","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/jvh.12414","article-title":"Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004\u20132011","volume":"22","author":"Tong","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Angeletti, A., Cantarelli, C., and Cravedi, P. (2019). HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00020"},{"key":"ref_34","first-page":"139","article-title":"Hepatitis C virus infection and glomerular disease","volume":"66","author":"Fabrizi","year":"2014","journal-title":"Minerva Urol. Nefrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2169\/internalmedicine.37.836","article-title":"Glomerulonephritis in Autopsy Cases with Hepatitis C Virus Infection","volume":"37","author":"Arase","year":"1998","journal-title":"Intern. Med."},{"key":"ref_36","first-page":"434","article-title":"Hepatitis C virus and its renal manifestations: A review and update","volume":"8","author":"Latt","year":"2012","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"Yildiz","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1681\/ASN.V101146","article-title":"Renal Thrombotic Microangiopathy Associated with Anticardiolipin Antibodies in Hepatitis C-Positive Renal Allograft Recipients","volume":"10","author":"Baid","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.04320416","article-title":"Viral-Associated GN: Hepatitis C and HIV","volume":"12","author":"Kupin","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hammerstad, S.S., Grock, S.F., Lee, H.J., Hasham, A., Sundaram, N., and Tomer, Y. (2015). Diabetes and Hepatitis C: A Two-Way Association. Front. Endocrinol., 6.","DOI":"10.3389\/fendo.2015.00134"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/hep.510300416","article-title":"Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection","volume":"30","author":"Caronia","year":"1999","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6150861","DOI":"10.1155\/2018\/6150861","article-title":"Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy","volume":"2018","author":"Drazilova","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jare.2016.07.004","article-title":"Hepatitis C and kidney disease: A narrative review","volume":"8","author":"Barsoum","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-3083.1995.tb03643.x","article-title":"The Aetiology of Mixed Cryoglobulinaemia Associated with Hepatitis C Virus Infection","volume":"42","author":"Agnello","year":"1995","journal-title":"Scand. J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.2009.247","article-title":"Hepatitis C virus\u2013induced cryoglobulinemia","volume":"76","author":"Charles","year":"2009","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins. A report of 86 cases","volume":"57","author":"Brouet","year":"1974","journal-title":"Am. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00002281-200201000-00006","article-title":"Cryoglobulinemia vasculitis","volume":"14","author":"Cacoub","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101575","DOI":"10.1016\/j.clinre.2020.11.005","article-title":"Hepatitis C virus-related vasculitis","volume":"45","author":"Boleto","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_49","unstructured":"Davuluri, S., and Vaqar, S. (2024, July 26). Cryoglobulinemic Vasculitis, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556045\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2249.1997.475-ce1383.x","article-title":"Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection","volume":"110","author":"Roccatello","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ki.1993.161","article-title":"Role of monocytes in cryoglobulinemia-associated nephritis","volume":"43","author":"Roccatello","year":"1993","journal-title":"Kidney Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02054025","article-title":"Clearance of cryoglobulins in man","volume":"10","author":"Ng","year":"1988","journal-title":"Springer Semin. Immunopathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/2040620715623924","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin\u2019s lymphomas: What do we know?","volume":"7","author":"Vannata","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2215\/CJN.06920711","article-title":"Hepatitis C Virus Infection and Kidney Disease: A meta analysis","volume":"7","author":"Fabrizi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/11.supp4.25","article-title":"Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis","volume":"11","author":"Fornasieri","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_58","first-page":"271","article-title":"The presence and possible role of monocyte infiltration in human chronic proliferative glomerulonephritides. Light microscopic, immunofluorescence, and histochemical correlations","volume":"94","author":"Monga","year":"1979","journal-title":"Am. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/01913128609064200","article-title":"Cell Interposition in Glomerular Capillary Walls in Cryoglobulinemic Glomerulonephritis (CRYGN). Ultrastructural Investigation of 23 Cases","volume":"10","author":"Mazzucco","year":"1986","journal-title":"Ultrastruct. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0002-9343(75)90480-5","article-title":"Mixed IgG-IgM cryoglobulinemia with glomerulonephritis. Immunochemical, fluorescent and ultrastructural study of kidney and in vitro cryoprecipitate","volume":"59","author":"Cordonnier","year":"1975","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.ajkd.2015.12.007","article-title":"AJKD Atlas of Renal Pathology: Cryoglobulinemic Glomerulonephritis","volume":"67","author":"Fogo","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0002-9343(99)00014-5","article-title":"Renal manifestations of hepatitis C infection","volume":"106","author":"Daghestani","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0002-9343(66)90200-2","article-title":"Cryoglobulinemia\u2014A clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity","volume":"40","author":"Meltzer","year":"1966","journal-title":"Am. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000516103","article-title":"Renal Disease in Cryoglobulinemia","volume":"1","author":"Menter","year":"2021","journal-title":"Glomerular Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000186573","article-title":"Hepatitis C Virus Infection and Membranous Glomerulonephritis","volume":"59","author":"Rollino","year":"1991","journal-title":"Nephron"},{"key":"ref_66","first-page":"323","article-title":"The Clinico-pathologic Features of Hepatitis B Virus-associated Glomerulonephritis","volume":"63","author":"Lai","year":"1987","journal-title":"QJM Int. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00467-002-0900-8","article-title":"Hepatitis B and C virus co-infection in black children with membranous nephropathy","volume":"17","author":"Sithebe","year":"2002","journal-title":"Pediatr. Nephrol."},{"key":"ref_68","first-page":"141","article-title":"Hepatitis C virus associated membranous glomerulonephritis","volume":"44","author":"Alpers","year":"1995","journal-title":"Clin. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Moroni, G., and Ponticelli, C. (2020). Secondary Membranous Nephropathy. A Narrative Review. Front. Med., 7.","DOI":"10.3389\/fmed.2020.611317"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.V62220","article-title":"Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan","volume":"6","author":"Yamabe","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000333772","article-title":"Hepatitis C and renal disease: Epidemiology, diagnosis, pathogenesis and therapy","volume":"176","author":"Morales","year":"2012","journal-title":"Contrib. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000045243","article-title":"Focal Segmental Glomerular Sclerosis among Patients Infected with Hepatitis C Virus","volume":"81","author":"Alpers","year":"1999","journal-title":"Nephron"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000168874","article-title":"Hepatitis C Associated Glomerulonephritis","volume":"15","author":"Altraif","year":"1995","journal-title":"Am. J. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2005.01.013","article-title":"HCV associated glomerulopathy in Egyptian patients: Clinicopathological analysis","volume":"334","author":"Sabry","year":"2005","journal-title":"Virology"},{"key":"ref_75","first-page":"83","article-title":"Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy","volume":"41","author":"Ezaki","year":"1999","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"ref_76","first-page":"49","article-title":"Focal segmental glomerulosclerosis and hepatitis C virus: A case report","volume":"43","author":"Motta","year":"2001","journal-title":"Panminerva Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5414\/CN107337","article-title":"Stabilization of Hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon \u03b1-2a and ribavirin","volume":"80","author":"Sperati","year":"2013","journal-title":"Clin. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3109\/0886022X.2013.815568","article-title":"Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis","volume":"35","author":"Shah","year":"2013","journal-title":"Ren. Fail."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.ackd.2015.06.003","article-title":"Glomerular Diseases Associated With Hepatitis B and C","volume":"22","author":"Gupta","year":"2015","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_80","first-page":"e27322","article-title":"Hepatitis Virus C-associated Nephropathy: A Review and Update","volume":"14","author":"Habas","year":"2022","journal-title":"Cureus"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: A working proposal","volume":"43","author":"Fogo","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/sj.ki.5000160","article-title":"Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants","volume":"69","author":"Thomas","year":"2006","journal-title":"Kidney Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.ackd.2014.02.010","article-title":"Morphologic Variants of Focal Segmental Glomerulosclerosis and Their Significance","volume":"21","author":"Stokes","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_84","unstructured":"Guruswamy Sangameswaran, K.D., Hashmi, M.F., and Baradhi, K.M. (2024, June 12). Focal Segmental Glomerulosclerosis, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532272\/."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cld.2017.03.005","article-title":"Renal Manifestations of Hepatitis C Virus","volume":"21","author":"Ferri","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Mazzaro, C., Quartuccio, L., Adinolfi, L.E., Roccatello, D., Pozzato, G., Nevola, R., Tonizzo, M., Gitto, S., Andreone, P., and Gattei, V. (2021). A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses, 13.","DOI":"10.3390\/v13112249"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000188494","article-title":"IgA Nephropathy Associated with Hepatitis C Virus Infection","volume":"69","author":"Gonzalo","year":"1995","journal-title":"Nephron"},{"key":"ref_88","first-page":"718","article-title":"IgA nephropathy associated with hepatitis C virus infection: A case report","volume":"18","author":"Ji","year":"2010","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0971-4065.109443","article-title":"Hepatitis C as a potential cause of IgA nephropathy","volume":"23","author":"Dey","year":"2013","journal-title":"Indian J. Nephrol."},{"key":"ref_90","first-page":"593","article-title":"Two cases of glomerulonephritis in one patient infected with the hepatitis C virus","volume":"33","author":"Molina","year":"2013","journal-title":"Nefrologia"},{"key":"ref_91","first-page":"21","article-title":"Association of IgA Nephropathy with Hepatitis C","volume":"17","author":"Malik","year":"2018","journal-title":"IOSR J. Dent. Med. Sci. (IOSR-JDMS)"},{"key":"ref_92","first-page":"714","article-title":"Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors","volume":"69","author":"Roccatello","year":"1993","journal-title":"Lab. Investig."},{"key":"ref_93","first-page":"3","article-title":"Glomerular changes in patients with cirrhosis of the liver","volume":"7","author":"Berger","year":"1977","journal-title":"Adv. Nephrol. Necker. Hosp."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1111\/hdi.12649","article-title":"Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis","volume":"22","author":"Rutledge","year":"2018","journal-title":"Hemodial. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2169\/internalmedicine.49.4365","article-title":"Successful Interferon-\u03b1 Treatment in a Patient with IgA Nephropathy Associated with Hepatitis C Virus Infection","volume":"49","author":"Ji","year":"2010","journal-title":"Intern. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000467","article-title":"Interferon treatment on glomerulonephritis associated with hepatitis C virus","volume":"15","author":"Matsumoto","year":"2000","journal-title":"Pediatr. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0272-6386(97)90020-2","article-title":"Fibrillary glomerulonephritis associated with hepatitis C viral infection","volume":"29","author":"Coroneos","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5414\/CNP60364","article-title":"Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection","volume":"60","author":"Guerra","year":"2003","journal-title":"Clin. Nephrol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/08860220802213062","article-title":"Fibrillary Glomerulonephritis with Hepatitis C Viral Infection and Hypocomplementemia","volume":"30","author":"Ray","year":"2008","journal-title":"Ren. Fail."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.V9122244","article-title":"Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy","volume":"9","author":"Markowitz","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1681\/ASN.2007070757","article-title":"Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy","volume":"19","author":"Alpers","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_102","first-page":"409","article-title":"Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy","volume":"141","author":"Yang","year":"1992","journal-title":"Am. J. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.ASN.0000013397.06964.19","article-title":"Immunotactoid Glomerulopathy","volume":"13","author":"Schwartz","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0272-6386(12)70138-5","article-title":"Morphologic and Clinical Features of Fibrillary Glomerulonephritis Versus Immunotactoid Glomerulopathy","volume":"22","author":"Fogo","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1046\/j.1523-1755.1998.t01-1-00094.x","article-title":"Fibrillary glomerulopathy","volume":"53","author":"Brady","year":"1998","journal-title":"Kidney Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11894-001-0045-0","article-title":"Kidney disease in patients with chronic hepatitis C","volume":"3","author":"Philipneri","year":"2001","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ki.1987.66","article-title":"Fibrillary glomerulonephritis: An entity with unusual immunofluorescence features","volume":"31","author":"Alpers","year":"1987","journal-title":"Kidney Int."},{"key":"ref_109","first-page":"279","article-title":"Fibrillary Renal Deposits and Nephritis","volume":"113","author":"Duffy","year":"1983","journal-title":"Am. J. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/ki.1992.433","article-title":"Clinical and pathologic features of fibrillary glomerulonephritis","volume":"42","author":"Iskandar","year":"1992","journal-title":"Kidney Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1478-3231.2011.02458.x","article-title":"Hepatitis C virus and kidney: A strong association with different clinical aspects","volume":"31","author":"Pipili","year":"2011","journal-title":"Liver Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/01.bor.0000198002.42826.c2","article-title":"Cryoglobulinemic vasculitis","volume":"18","author":"Ferri","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_113","unstructured":"Bhandari, J., Awais, M., and Aeddula, N.R. (2024). Cryoglobulinemia. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0168-8278(94)80137-1","article-title":"High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobulinemia","volume":"21","author":"Bichard","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2022). KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int., 102, S129\u2013S205.","DOI":"10.1016\/j.kint.2022.07.013"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/rheumatology\/kem132","article-title":"Hepatitis C-associated mixed cryoglobulinaemia: A crossroad between autoimmunity and lymphoproliferation","volume":"46","author":"Saadoun","year":"2007","journal-title":"Rheumatology"},{"key":"ref_117","first-page":"109","article-title":"Systemic vasculitis in patients with hepatitis C","volume":"28","author":"Cacoub","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_118","unstructured":"Stanton, M., and Tiwari, V. (2024). Polyarteritis Nodosa. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_119","first-page":"79","article-title":"Severe necroziting vasculitis in a patient with hepatitis C virus infection treated by interferon","volume":"14","author":"Pateron","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcv.2004.10.003","article-title":"Polyarteritis nodosa after interferon treatment for chronic hepatitis C","volume":"32","author":"Busteros","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000441-200606000-00008","article-title":"Polyarteritis Nodosa and Cryoglobulinemia Glomerulonephritis Related to Chronic Hepatitis C","volume":"331","author":"Canada","year":"2006","journal-title":"Am. J. Med. Sci."},{"key":"ref_122","first-page":"439","article-title":"Life-Threatening Hepatitis C Virus\u2013Associated Polyarteritis Nodosa Successfully Treated by Rituximab","volume":"17","author":"Masseau","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1752-1947-6-305","article-title":"Classic polyarteritis nodosa associated with hepatitis C virus infection: A case report","volume":"6","author":"Rodrigo","year":"2012","journal-title":"J. Med. Case Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3748\/wjg.v27.i18.2073","article-title":"Immune disorders and rheumatologic manifestations of viral hepatitis","volume":"27","author":"Maslennikov","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.20381","article-title":"Hepatitis C virus\u2013associated polyarteritis nodosa","volume":"63","author":"Saadoun","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jare.2016.11.002","article-title":"Vasculitic syndromes in hepatitis C virus: A review","volume":"8","author":"Ragab","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Priora, M., Borrelli, R., Parisi, S., Ditto, M.C., Realmuto, C., Lagan\u00e0, A., Di Vittorio, C.C., Degiovanni, R., Peroni, C.L., and Fusaro, E. (2021). Autoantibodies and Rheumatologic Manifestations in Hepatitis C Virus Infection. Biology, 10.","DOI":"10.3390\/biology10111071"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_129","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Re, V.L., and AASLD-IDSA HCV Guidance Panel (Clin. Infect. Dis., 2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection, Clin. Infect. Dis., ahead-of-print."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.34067\/KID.0001812021","article-title":"Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease","volume":"2","author":"Strohbehn","year":"2021","journal-title":"Kidney360"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-Induced Anemia: Mechanisms, Risk Factors and Related Targets for Future Research","volume":"13","author":"Russmann","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"431","DOI":"10.14218\/JCTH.2018.00007","article-title":"Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era","volume":"6","author":"Mathur","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4254\/wjh.v14.i6.1053","article-title":"Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection","volume":"14","author":"Salama","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jrenhep.2019.43","article-title":"Hepatitis C Virus Infection and Renal Disorders","volume":"3","author":"Salvadori","year":"2019","journal-title":"J. Ren. Hepatic Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/2175-8239-jbn-2019-0165","article-title":"Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy","volume":"43","author":"Arruda","year":"2021","journal-title":"J. Bras. Nefrol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/1389450116666150825111314","article-title":"Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues","volume":"18","author":"Feld","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_139","first-page":"CD012143","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"2017","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Fabrizi, F., Cerutti, R., Porata, G., Messa, P., and Ridruejo, E. (2019). Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. Pathogens, 8.","DOI":"10.3390\/pathogens8040176"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejr.2022.12.004","article-title":"Effectiveness of direct-acting antiviral (DAA) agents on hepatitis C virus-related mixed cryoglobulinemia syndrome: One-year follow-up","volume":"45","author":"Fayed","year":"2023","journal-title":"Egypt. Rheumatol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Danishwar, M., Jamil, Z., Khan, S., Nakhla, M., Ahmad, I., Ali, M.A., and Lau, D.T.Y. (2022). Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040984"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10238-022-00808-1","article-title":"The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements","volume":"23","author":"Dammacco","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of Action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000445841","article-title":"Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study","volume":"43","author":"Roccatello","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/039139880703000513","article-title":"Hepatitis C Virus Infection and Rituximab Therapy after Renal Transplantation","volume":"30","author":"Fabrizi","year":"2007","journal-title":"Int. J. Artif. Organs"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?","volume":"61","author":"Lok","year":"2015","journal-title":"Hepatology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.10107","article-title":"Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies","volume":"46","author":"Vassilopoulos","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0272-6386(95)90557-X","article-title":"Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"25","author":"Quigg","year":"1995","journal-title":"Am. J. Kidney Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5414\/CNP75374","article-title":"Cryoglobulinemic membranoproliferative glomerulonephritis: Beyond conventional therapy","volume":"75","author":"Colucci","year":"2011","journal-title":"Clin. Nephrol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/ndt\/16.4.869-a","article-title":"Hepatitis C-associated glomerulonephritis\u2014A novel therapeutic approach","volume":"16","author":"Reed","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(05)66583-X","article-title":"Glomerulonephritis","volume":"365","author":"Chadban","year":"2005","journal-title":"Lancet"},{"key":"ref_159","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl., 3, 1\u2013150."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Chen, Y., Shen, X., Liang, H., Li, G., Han, K., Liang, C., and Hao, Z. (2022). Relationship between hepatitis C and kidney stone in US females: Results from the National Health and Nutrition Examination Survey in 2007\u20132018. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.940905"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1023\/A:1010789425975","article-title":"CASE REPORT: Uric Acid Nephrolithiasis Associated with Interferon and Ribavirin Treatment of Hepatitis C","volume":"46","author":"Fontana","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1681\/ASN.2016010030","article-title":"Hepatitis C Virus Infection in Chronic Kidney Disease","volume":"27","author":"Ladino","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_164","unstructured":"Centers for Disease Control and Prevention (2024, August 11). Chronic Kidney Disease in the United States, Available online: https:\/\/www.cdc.gov\/kidney-disease\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jvh.12413","article-title":"A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection","volume":"22","author":"Park","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.18632\/oncotarget.12896","article-title":"A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease?","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5604\/01.3001.0011.7382","article-title":"Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"17","author":"Fabrizi","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3748\/wjg.v25.i4.398","article-title":"Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression","volume":"25","author":"Ganesan","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus\u2013Monoinfected Patients","volume":"160","author":"Re","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jmv.24353","article-title":"Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis","volume":"88","author":"Fabrizi","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0b013e3283574e71","article-title":"Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients","volume":"26","author":"Peters","year":"2012","journal-title":"AIDS"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1093\/cid\/ciu617","article-title":"Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"59","author":"Lucas","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.aje.a116137","article-title":"Prevalence of Antibody to Hepatitis C Virus in Hemodialysis Patients","volume":"134","author":"Hayashi","year":"1991","journal-title":"Am. J. Epidemiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","article-title":"Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients","volume":"16","author":"Espinosa","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: Hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1492-7535.2005.01129.x","article-title":"Chronic viral hepatitis in hemodialysis patients","volume":"9","author":"Tang","year":"2005","journal-title":"Hemodial. Int."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s40620-022-01483-x","article-title":"The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: A meta-analysis","volume":"35","author":"Greeviroj","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Kenfack-Momo, R., Ngounoue, M.D., Kenmoe, S., Takuissu, G.R., Ebogo-Belobo, J.T., Kengne-Nd\u00e9, C., Mbaga, D.S., Menkem, E.Z., Fogang, R.L., and Tchatchouang, S. (2024). Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0284169"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3748\/wjg.v20.i11.2948","article-title":"Current testing strategies for hepatitis C virus infection in blood donors and the way forward","volume":"20","author":"Marwaha","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/ice.2015.247","article-title":"A Large Outbreak of Hepatitis C Virus Infections in a Hemodialysis Clinic","volume":"37","author":"Nguyen","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_185","first-page":"002","article-title":"Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit","volume":"S10","author":"Thompson","year":"2012","journal-title":"J. Nephrol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis","volume":"12","author":"Goodkin","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (2016). CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis. Am. J. Transpl., 16, 1633\u20131634.","DOI":"10.1111\/ajt.13811"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5500\/wjt.v13.i2.44","article-title":"Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States","volume":"13","author":"Yuan","year":"2023","journal-title":"World J. Transplant."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Fabrizi, F., Cerutti, R., Alfieri, C.M., and Messa, P. (2021). Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040496"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40620-018-0476-4","article-title":"HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)","volume":"31","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/ajt.12835","article-title":"Hepatitis C Virus Infection and Kidney Transplantation in 2014: What\u2019s New?","volume":"14","author":"Pascual","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.kint.2017.10.024","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient","volume":"93","author":"Chute","year":"2018","journal-title":"Kidney Int."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy","volume":"80","author":"Farris","year":"2011","journal-title":"Kidney Int."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-Transplant Diabetes Mellitus and HCV Seropositive Status After Renal Transplantation: Meta-Analysis of Clinical Studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am. J. Transplant."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2018). KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. Suppl., 8, 91\u2013165.","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ajkd.2003.09.018","article-title":"The impact of hepatitis c virus viremia on renal graft and patient survival: A 9-year prospective study","volume":"43","author":"Mahmoud","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_198","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2008). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl., 73, S1\u2013S2."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0272-6386(97)90345-0","article-title":"The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients","volume":"29","author":"Knoll","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5500\/wjt.v8.i4.84","article-title":"Hepatitis C and renal transplantation in era of new antiviral agents","volume":"8","author":"Salvadori","year":"2018","journal-title":"World J. Transplant."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","article-title":"Evidence that Clearance of Hepatitis C Virus RNA after \u03b1-Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation","volume":"14","author":"Kamar","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients","volume":"23","author":"Nicot","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_203","unstructured":"(2021, May 04). Organ Procurement and Transplantation Network, Available online: http:\/\/optn.transplant.hrsa.gov."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/0886022X.2022.2047069","article-title":"Utilization of HCV viremic donors in kidney transplantation: A chance or a threat?","volume":"44","author":"Czarnecka","year":"2022","journal-title":"Ren. Fail."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in Drug and Opioid-Involved Overdose Deaths\u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of Hepatitis C-Positive Kidneys for Hepatitis C-Positive Recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.ajkd.2022.12.019","article-title":"Kidney Transplantation From Hepatitis C Virus\u2013Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update","volume":"82","author":"Gordon","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment With Ledipasvir\u2013Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40620-019-00608-z","article-title":"Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection","volume":"32","author":"Coppola","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2020","journal-title":"Kidney Int."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.29125","article-title":"Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection","volume":"66","author":"Hogan","year":"2017","journal-title":"Hepatology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ekir.2016.06.006","article-title":"Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy","volume":"1","author":"Sise","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2015.391","article-title":"Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury","volume":"111","author":"Wanchoo","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.14309\/crj.2017.84","article-title":"Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir","volume":"4","author":"Ashraf","year":"2017","journal-title":"ACG Case Rep. J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4254\/wjh.v8.i32.1343","article-title":"Anti-hepatitis C virus drugs and kidney","volume":"8","author":"Carrier","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.dld.2019.11.006","article-title":"Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study","volume":"52","author":"Pasulo","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_219","first-page":"345","article-title":"Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection","volume":"39","author":"Cha","year":"2014","journal-title":"P T"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/jvh.13193","article-title":"Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience","volume":"26","author":"Tsai","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s15010-020-01505-5","article-title":"Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy","volume":"48","author":"Abdellatif","year":"2020","journal-title":"Infection"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Czarnecka, P., Czarnecka, K., Tronina, O., B\u0105czkowska, T., Wycza\u0142kowska-Tomasik, A., Durlik, M., and Czerwinska, K. (2023). Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103513"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:03Z","timestamp":1760111943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":224,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jcm13185536"],"URL":"https:\/\/doi.org\/10.3390\/jcm13185536","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}